The 10 key factors delaying patient access across Europe (Guest blog)

Most patients in European countries have to wait much longer than needed to access new cancer medicines. All European countries face delays in giving patients access new treatments. How come? As part of the Time to Patient Initiative, we identified ten reasons that explain most delays. These reasons relate to the reimbursement process, the reimbursement criteria and health system readiness.

Read the full blog here.

Christel Jansen

Christel Jansen is a manager at Vintura.
Read Morechevron_right